Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

ClinicalTrials.gov ID: NCT03370133

Public ClinicalTrials.gov record NCT03370133. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 10:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Study identification

NCT ID
NCT03370133
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
UCB Biopharma SRL
Industry
Enrollment
567 participants

Conditions and interventions

Interventions

  • Bimekizumab Drug
  • Placebo Other
  • Ustekinumab Drug

Drug · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 5, 2017
Primary completion
Jan 7, 2019
Completion
Dec 12, 2019
Last update posted
Apr 14, 2026

2017 – 2019

United States locations

U.S. sites
25
U.S. states
17
U.S. cities
25
Facility City State ZIP Site status
Ps0009 946 Phoenix Arizona 85032
Ps0009 910 Bakersfield California 93309
Ps0009 919 San Diego California 92103
Ps0009 906 Boca Raton Florida 33486
Ps0009 909 Boynton Beach Florida 33437
Ps0009 912 Coral Gables Florida 33134
Ps0009 907 Miami Florida 33144
Ps0009 903 Ocala Florida 34471
Ps0009 921 Ormond Beach Florida 32174
Ps0009 918 Tampa Florida 33612
Ps0009 941 Alpharetta Georgia 30022
Ps0009 911 Plainfield Indiana 46168
Ps0009 900 West Des Moines Iowa 50265
Ps0009 905 Overland Park Kansas 66215
Ps0009 922 Baton Rouge Louisiana 70809
Ps0009 917 Troy Michigan 48084
Ps0009 915 St Louis Missouri 63117
Ps0009 958 Omaha Nebraska 68144
Ps0009 901 Portsmouth New Hampshire 03801
Ps0009 908 East Windsor New Jersey 08520
Ps0009 923 Albuquerque New Mexico 87106
Ps0009 913 New York New York 10029-65
Ps0009 920 Portland Oregon 97210
Ps0009 924 Houston Texas 77004
Ps0009 914 San Antonio Texas 78213

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 80 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03370133, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 14, 2026 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03370133 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →